Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema

Active, not recruiting

• Conditions: Retinal Vein Occlusion

• Registration Number: NCT07106268
• Lead Sponsor: Tianjin Medical University Eye Hospital

Brief Summary

the goal of this observational study is to the find the molecular mechanisms underlying the prognosis process of Retinal vein occlusion in patients with retinal vein occlusion . The main question it aims to answer is:

What are the changes in protein in the aqueous humor during treatment in patients who are sensitive to anti-VEGF drug therapy?

Detailed Description

Not available

Study Timeline

• Study Start: 2023-03-01
• Study First Submitted: 2025-07-30
• Study First Submitted QC: 2025-07-30
• Status Verified: 2025-08
• Last Update Submitted: 2025-08-05
• Study First Posted: 2025-08-06
• Last Update Posted: 2025-08-07
• Primary Completion: 2025-09-30
• Study Completion: 2025-09-30

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Cystic or diffuse edema in the macular area, retinal vein tortuous dilation with hemorrhage
• Optical coherence tomography (OCT) examination showed that the macular area was raised, edema and thickened
• Monocular disease, baseline central retinal thickness (CRT) ≥ 250mm
• Intravitreal injection, laser photocoagulation and blood circulation and blood stasis removal drugs were not treated before surgery
• The patient had normal blood pressure, negative urine protein, normal liver and kidney function, and normal electrocardiogram

Exclusion Criteria

• Patients with fluorescein fundus angiography (FFA) showing a large area (10 optic disc areas) without perfusion requiring retinal photocoagulation
• Patients with chronic dacryocystitis, glaucoma, cataract, severe proliferative vitreoretinopathy or vitreous hemorrhage, epi macular membrane or macular ischemia, diabetic retinopathy, age-related macular degeneration, ocular trauma and other diseases
• Intravitreal therapy or laser photocoagulation with corticosteroids or anti-VEGF drugs within three months before the study

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Central retinal thickness	March 2023 - June 2024	The Heidelberg Optical Coherence Tomography scanner was used to detect the central retinal thickness in patients

Secondary Outcome Measures

Name	Time	Method
Best corrected visual acuity	March 2023 - June 2024	BCVA was measured using logarithm of the minimum angle of resolution (LogMAR) chart

Trial Locations

Locations (1)

Tianjin medical university eye hospital; 🇨🇳 Tianjin, province, China